Posted by Michael Wonder on 07 May 2025
Viridian Therapeutics receives FDA breakthrough therapy designation for veligrotug for the treatment of thyroid eye disease
7 May 2025 - Biologics license application submission for veligrotug on track for second half 2025 with a planned US launch in 2026, if approved.
Viridian Therapeutics today announced that the US FDA granted breakthrough therapy designation to veligrotug, the company’s lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of thyroid eye disease.
